Clinical Trials & Research

8 articles in Clinical Trials & Research

Cognitive Health & Aging

Peptide Biomarkers for Aging & Longevity

Plasma GHK-Cu declines from roughly 200 ng/mL at age 20 to 80 ng/mL by age 60—a pattern that has prompted researchers to examine peptide biomarkers in aging and whether shifts in circulating humanin and related peptides track longevity signaling pathways.

AdminUpdated Aug 1910 min

Cognitive Health & Aging

GLP-1 Receptor Agonists and Brain Neuroprotection

In 2021, researchers at Lund University began testing exenatide, a GLP-1 receptor agonist, for potential neuroprotection in Parkinson's disease—a use far removed from its original approval for type 2 diabetes.

AdminUpdated Aug 19 min

Cognitive Health & Aging

Tesamorelin and Cognitive Health in Aging

Emerging research reveals tesamorelin's surprising impact on cognitive function in aging, moving beyond traditional growth hormone applications to target brain health directly.

AdminUpdated Jul 2812 min

Cognitive Health & Aging

Selank Semax Stack: Cognitive Nootropic Peptides

Discover how the Selank and Semax stack cognitive nootropic peptides combination enhances mental performance beyond single-peptide use, with emerging research showing synergistic benefits for focus, anxiety, and cognitive clarity.

AdminUpdated Jul 2811 min

Regulatory & Approval Status

Why BPC-157 Isn't FDA Approved Yet

After 30 years and 150 peer-reviewed publications, BPC-157 remains without FDA approval—a puzzle that reveals how regulatory pathways, funding constraints, and the absence of large-scale human trials can stall a compound indefinitely.

AdminUpdated Jul 2810 min

Clinical Trials & Research

Retatrutide HbA1c Reduction Diabetes Study

Discover how retatrutide's impressive mean body weight loss complements its potential in blood sugar control, supported by the latest retatrutide HbA1c reduction diabetes study, offering new hope for managing type 2 diabetes effectively.

AdminUpdated Jul 2813 min

Clinical Trials & Research

TRIUMPH Trial Retatrutide Phase 3 Obesity Study

Discover the groundbreaking TRIUMPH trial for retatrutide and its pivotal role in the phase 3 obesity journey towards FDA approval, revealing astonishing weight loss results and new hope for effective obesity treatments.

AdminUpdated Jul 2811 min

Clinical Trials & Research

Retatrutide NEJM 2023 Phase 2 Obesity Results

The retatrutide NEJM 2023 phase 2 obesity trial reveals groundbreaking weight loss results, with participants losing an average of 24.2% of their body weight — but what does the data truly convey about its potential in obesity treatment?

AdminUpdated Jul 2813 min